All variables studied—HR status, ET therapy, age, clinical stage, clinical response, HER2 status, histological grade, and the number of lymph node metastases—were associated with the time to recurrence or death. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.